KDIGO Updates AKI Guidelines for First Time in Over a Decade, Boosting BioPorto’s NGAL Biomarker

Event summary

  • KDIGO published its 2026 Clinical Practice Guideline Draft for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD), the first major update since 2012.
  • The draft emphasizes early detection, risk prediction, and biomarker-enabled identification of AKI, aligning with BioPorto’s NGAL biomarker technology.
  • KDIGO’s updated framework includes improved clinical decision support tools, enhanced risk stratification, and updated recommendations for fluid management and follow-up care.
  • The draft is open for public review until April 27, 2026.

The big picture

The KDIGO 2026 guideline update reflects a global shift toward earlier identification and intervention in acute kidney disorders, validating BioPorto’s focus on NGAL as a critical biomarker. This update could enhance BioPorto’s competitive edge in the in vitro diagnostics space, particularly as healthcare systems increasingly prioritize early detection and personalized patient management. The inclusion of NGAL in clinical practice guidelines may also drive demand for BioPorto’s existing and future diagnostic products.

What we're watching

Biomarker Adoption
How the inclusion of NGAL in KDIGO’s guidelines will accelerate its adoption in clinical practice and impact BioPorto’s market position.
Regulatory Validation
Whether the updated guidelines will lead to broader regulatory approvals for BioPorto’s NGAL-based tests in key markets.
Competitive Dynamics
The pace at which competitors develop alternative biomarkers or diagnostic tools in response to KDIGO’s updated framework.